DK1453487T3 - Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud - Google Patents

Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud

Info

Publication number
DK1453487T3
DK1453487T3 DK01995903T DK01995903T DK1453487T3 DK 1453487 T3 DK1453487 T3 DK 1453487T3 DK 01995903 T DK01995903 T DK 01995903T DK 01995903 T DK01995903 T DK 01995903T DK 1453487 T3 DK1453487 T3 DK 1453487T3
Authority
DK
Denmark
Prior art keywords
coating layer
poly
methacrylic acid
methyl methacrylate
dosage form
Prior art date
Application number
DK01995903T
Other languages
Danish (da)
English (en)
Inventor
Gregory Paul Dittmar
Joseph Michael Amante
Tony Ryan Cronk
Daniel Gary Newby
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32823137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1453487(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of DK1453487T3 publication Critical patent/DK1453487T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01995903T 2001-11-23 2001-11-23 Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud DK1453487T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/043893 WO2003045356A1 (en) 2000-11-20 2001-11-23 Pharmaceutical dosage form with multiple coatings

Publications (1)

Publication Number Publication Date
DK1453487T3 true DK1453487T3 (da) 2008-07-21

Family

ID=32823137

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01995903T DK1453487T3 (da) 2001-11-23 2001-11-23 Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud

Country Status (15)

Country Link
EP (1) EP1453487B2 (enExample)
JP (1) JP4999037B2 (enExample)
CN (1) CN1314390C (enExample)
AT (1) ATE389389T1 (enExample)
AU (1) AU2002226955B2 (enExample)
BR (1) BRPI0117180B8 (enExample)
DE (1) DE60133319T3 (enExample)
DK (1) DK1453487T3 (enExample)
ES (1) ES2301575T5 (enExample)
HU (1) HU231030B1 (enExample)
IL (1) IL161628A (enExample)
MX (1) MXPA04004747A (enExample)
NZ (1) NZ532564A (enExample)
PT (1) PT1453487E (enExample)
WO (1) WO2003045356A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PT2446881E (pt) * 2003-07-24 2014-06-11 Glaxosmithkline Llc Películas de dissolução oral
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
ES2323536T3 (es) * 2004-09-01 2009-07-20 The Procter And Gamble Company Composiciones que comprenden acido-5-amino-2-hidroxibenzoico yh un azucar reductor.
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2012107058A (ja) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc 複数のコーティングを有する医薬剤形
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
GB2510754B (en) * 2013-02-12 2016-07-13 Diurnal Ltd Controlled drug release
TWI688411B (zh) * 2013-02-22 2020-03-21 日商志瑞亞新藥工業股份有限公司 腸溶錠
JP6165022B2 (ja) * 2013-10-30 2017-07-19 株式会社ファンケル 放出制御型ソフトカプセル剤
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
CN107661370A (zh) * 2017-11-20 2018-02-06 贵州浩诚药业有限公司 一种苦参片及其制备方法
JP2021528483A (ja) * 2018-05-03 2021-10-21 エムダブリュ エンキャップ リミテッド 下部胃腸管への医薬の送達のための剤形
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
CN113993509A (zh) * 2019-05-15 2022-01-28 赢创运营有限公司 用胶囊填充机制备具有基于(甲基)丙烯酸酯共聚物的包衣的填充硬壳胶囊的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets

Also Published As

Publication number Publication date
ES2301575T5 (es) 2022-04-22
AU2002226955A1 (en) 2003-06-10
IL161628A0 (en) 2004-09-27
EP1453487B1 (en) 2008-03-19
MXPA04004747A (es) 2004-08-02
DE60133319D1 (de) 2008-04-30
NZ532564A (en) 2006-06-30
HUP0402230A2 (hu) 2005-02-28
BRPI0117180B1 (pt) 2018-12-04
WO2003045356A1 (en) 2003-06-05
BRPI0117180B8 (pt) 2021-05-25
EP1453487B2 (en) 2021-03-31
HUP0402230A3 (en) 2008-04-28
ATE389389T1 (de) 2008-04-15
BR0117180A (pt) 2004-11-03
AU2002226955B2 (en) 2006-04-27
DE60133319T2 (de) 2009-04-30
DE60133319T3 (de) 2021-08-05
CN1314390C (zh) 2007-05-09
HU231030B1 (hu) 2019-12-30
CN1558754A (zh) 2004-12-29
JP4999037B2 (ja) 2012-08-15
ES2301575T3 (es) 2008-07-01
JP2005510539A (ja) 2005-04-21
PT1453487E (pt) 2008-05-13
IL161628A (en) 2014-03-31
EP1453487A1 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
WO2004108162A3 (en) Controlled release pharmaceutical composition
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
ES2611995T3 (es) Métodos y composiciones para el suministro de un agente terapéutico
JP2005515966A5 (enExample)
NO20030897L (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
JPH059412B2 (enExample)
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
JP2007536311A5 (enExample)
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
JP2026065074A (ja) 新規多機能オリゴペプチド
US20200323834A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof
JP2021535163A5 (enExample)
TR200103144T2 (tr) Yeni bileşikler
CA2444814A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EE200200556A (et) Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon
MA27157A1 (fr) Methode de traitement d'affections osseuses.
CA2472449A1 (en) Pharmaceutical composition for oral use with improved absorption